Gleevec® (imatinib mesylate) | Novartis United States of America
Gleevec® (imatinib mesylate) Product Information. Active ingredients - tablets. for oral use. Information Resources. Downloadable Content . Resources. ... Other Novartis US websites Other Novartis US websites. Oncology HCP resources; Medical …
Gleevec is a kinase inhibitor indicated for the treatment of: •Newly diagnosed adult and pediatric patients with Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in chronic
Imatinib - Wikipedia
Imatinib, sold under the brand names Gleevec and Glivec (both marketed worldwide by Novartis) among others, is an oral targeted therapy medication used to treat cancer. [2] Imatinib is a small molecule inhibitor targeting multiple tyrosine kinases such as CSF1R, ABL, c …
Video: Gleevec Receives US Approval as First Treatment To ... - Novartis
2008年12月20日 · Gleevec is now approved for nine indications, including the treatment of Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML), Kit (CD117)-positive gastrointestinal stromal tumors which cannot be surgically removed and/or have already spread to other parts of the body (metastasized) and five other rare diseases. Filing data.
Information on Gleevec (Imatinib Mesylate) | FDA
Gleevec is approved to treat a rare cancer called Chronic Myeloid Leukemia (CML).
Gleevec: the Breakthrough in Cancer Treatment
With Gleevec, a remarkable cancer drug, the approach was to target the disease at the cellular and subcellular level. Some say it's a miracle drug. Others call it a silver bullet. Gleevec, also...
Gleevec: Uses, Dosage, Side Effects - Drugs.com
2023年8月23日 · Gleevec is a targeted therapy cancer treatment used to treat specific types of leukemia (blood cancer), bone marrow disorders, skin cancers and certain tumors of the stomach and digestive system. Gleevec (imatinib) is an oral tablet that is taken once or twice a day.
How Gleevec Transformed Leukemia Treatment - NCI
This story outlines the discovery of imatinib (Gleevec), a ground-breaking drug that transformed the treatment of chronic myelogenous leukemia and sparked the beginnings of precision medicine.
How does Gleevec (imatinib) work? - Drugs.com
2024年2月15日 · Targeted drugs are designed to work by focusing on a specific feature or mutation of the cancer cells that allows them to grow and multiply. Gleevec, from Novartis Pharmaceuticals, was the first medicine approved by the FDA in 2001 to specifically block the BCR-ABL tyrosine kinase protein, a target for certain forms of leukemia.
Gleevec®/Glivec® | Novartis
Resources for physicians and other healthcare professionals including clinical trial recruiting, grant funding, congresses and country-level information. Discover how Novartis turns breakthrough science into transformative, high-value treatments.